113 related articles for article (PubMed ID: 11440140)
1. Introduction of a low molecular weight agonist peptide for complement C3a receptor into soybean proglycinin A1aB1b subunit by site-directed mutagenesis.
Takenaka Y; Utsumi S; Yoshikawa M
Biosci Biotechnol Biochem; 2001 May; 65(5):1202-5. PubMed ID: 11440140
[TBL] [Abstract][Full Text] [Related]
2. Introduction of enterostatin (VPDPR) and a related sequence into soybean proglycinin A1aB1b subunit by site-directed mutagenesis.
Takenaka Y; Utsumi S; Yoshikawa M
Biosci Biotechnol Biochem; 2000 Dec; 64(12):2731-3. PubMed ID: 11210149
[TBL] [Abstract][Full Text] [Related]
3. Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin, a bioactive peptide derived from rice albumin.
Takahashi M; Moriguchi S; Ikeno M; Kono S; Ohata K; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
Peptides; 1996; 17(1):5-12. PubMed ID: 8822503
[TBL] [Abstract][Full Text] [Related]
4. Identification of casoxin C, an ileum-contracting peptide derived from bovine kappa-casein, as an agonist for C3a receptors.
Takahashi M; Moriguchi S; Suganuma H; Shiota A; Tani F; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
Peptides; 1997; 18(3):329-36. PubMed ID: 9145417
[TBL] [Abstract][Full Text] [Related]
5. Amino acid sequence analysis of bitter peptides from a soybean proglycinin subunit synthesized in Escherichia coli.
Kim MR; Choi SY; Kim CS; Kim CW; Utsumi S; Lee CH
Biosci Biotechnol Biochem; 1999 Dec; 63(12):2069-74. PubMed ID: 10664840
[TBL] [Abstract][Full Text] [Related]
6. Design of genetically modified soybean proglycinin A1aB1b with multiple copies of bioactive peptide sequences.
Prak K; Maruyama Y; Maruyama N; Utsumi S
Peptides; 2006 Jun; 27(6):1179-86. PubMed ID: 16356590
[TBL] [Abstract][Full Text] [Related]
7. Introduction of DPR, an enterostatin fragment peptide, into soybean beta-conglycinin alpha' subunit by site-directed mutagenesis.
Takenaka Y; Doyama N; Maruyama N; Utsumi S; Yoshikawa M
Biosci Biotechnol Biochem; 2004 Jan; 68(1):253-6. PubMed ID: 14745196
[TBL] [Abstract][Full Text] [Related]
8. Production of a bioactive peptide (IIAEK) in Escherichia coli using soybean proglycinin A1ab1b as a carrier.
Prak K; Utsumi S
J Agric Food Chem; 2009 May; 57(9):3792-9. PubMed ID: 19298043
[TBL] [Abstract][Full Text] [Related]
9. Improved bile acid-binding ability of soybean glycinin A1a polypeptide by the introduction of a bile acid-binding peptide (VAWWMY).
Choi SK; Adachi M; Utsumi S
Biosci Biotechnol Biochem; 2004 Sep; 68(9):1980-3. PubMed ID: 15388976
[TBL] [Abstract][Full Text] [Related]
10. N-glycosylation does not affect assembly and targeting of proglycinin in yeast.
Katsube T; Kang IJ; Takenaka Y; Adachi M; Maruyama N; Morisaki T; Utsumi S
Biochim Biophys Acta; 1998 Jan; 1379(1):107-17. PubMed ID: 9468338
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of oryzatensin: a novel bioactive peptide with ileum-contracting and immunomodulating activities derived from rice albumin.
Takahashi M; Moriguchi S; Yoshikawa M; Sasaki R
Biochem Mol Biol Int; 1994 Aug; 33(6):1151-8. PubMed ID: 7804141
[TBL] [Abstract][Full Text] [Related]
12. Active recombinant C3a of human anaphylatoxin produced in Escherichia coli.
Fukuoka Y; Yasui A; Tachibana T
Biochem Biophys Res Commun; 1991 Mar; 175(3):1131-8. PubMed ID: 2025244
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the solubility and emulsifying property of soybean proglycinin and rapeseed procruciferin in relation to structure modified by protein engineering.
Tandang MR; Atsuta N; Maruyama N; Adachi M; Utsumi S
J Agric Food Chem; 2005 Nov; 53(22):8736-44. PubMed ID: 16248579
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of soybean proglycinin A1aB1b homotrimer.
Adachi M; Takenaka Y; Gidamis AB; Mikami B; Utsumi S
J Mol Biol; 2001 Jan; 305(2):291-305. PubMed ID: 11124907
[TBL] [Abstract][Full Text] [Related]
15. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
[TBL] [Abstract][Full Text] [Related]
16. Modification tolerability of soybean proglycinin.
Gidamis AB; Wright P; Haque ZU; Katsube T; Kito M; Utsumi S
Biosci Biotechnol Biochem; 1995 Aug; 59(8):1593-5. PubMed ID: 7549110
[TBL] [Abstract][Full Text] [Related]
17. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.
Bubeck P; Grötzinger J; Winkler M; Köhl J; Wollmer A; Klos A; Bautsch W
Eur J Biochem; 1994 Feb; 219(3):897-904. PubMed ID: 8112341
[TBL] [Abstract][Full Text] [Related]
18. C-terminus engineering of soybean proglycinin: improvement of emulsifying properties.
Prak K; Nakatani K; Maruyama N; Utsumi S
Protein Eng Des Sel; 2007 Sep; 20(9):433-42. PubMed ID: 17720751
[TBL] [Abstract][Full Text] [Related]
19. The active site of human C4a anaphylatoxin.
Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
[TBL] [Abstract][Full Text] [Related]
20. Design and production of genetically modified soybean protein with anti-hypertensive activity by incorporating potent analogue of ovokinin(2-7).
Matoba N; Doyama N; Yamada Y; Maruyama N; Utsumi S; Yoshikawa M
FEBS Lett; 2001 May; 497(1):50-4. PubMed ID: 11376661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
